慢性乙型肝炎治愈新药研究进展

doi:10.3969/j.issn.1672-5069.2019.03.003

摘要/Abstract

Key words: Hepatitis B, Antiviral therapy, New medicine

张茜, 胡鹏. 慢性乙型肝炎治愈新药研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 313-317.

Zhang Qian, Hu Peng. Highlights in antiviral therapy for chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 313-317.

[1] Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet,2012,380(9859):2095-2128.
[2] Lu FM,Zhuang H.Management of hepatitis B in China. Chin Med J,2009,122(1):3-4.
[3] Lok AS,Zoulim F,Dusheiko G,et al.Hepatitis B cure:From discovery to regulatory approval. Hepatology,2017,66(4):1296-1313.
[4] BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(5):S45-S55.
[5] Trepo C,Chan HLY,Lok A.Hepatitis B virus infection. Lancet,2014,384(9959):2053-2063.
[6] Yapali S,Talaat N,Lok AS.Management of hepatitis B:Our practice and how it relates to the guidelines. Clin Gastroenterol H,2014,12(1):16-26.
[7] Hu P,Dou XG,Jiang JN,et al.Increased and sustained HBsAg loss in HBeAg positive CHB patients switched from NUC to Peg-IFN alfa-2a:A randomised open label trial(NEW SWITCH study). Hepatology,2016,64:36a-37a.
[8] Qiu K,Liu B,Li SY,et al.Systematic review with meta-analysis:combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharm Ther,2018,47(10):1340-1348.
[9] Heiner Wedemeyer KS,Bogomolov PO,Voronkova NV, et al.Interim results of a multicentre,open label phase 2 clinical trial (MYR203) to assess safety and effcacy of myrcludex B in combination with peg-interferon alpha 2a in patients with chronic HBV/HDV co-infection. Hepatology,2018,68:11A.
[10] Lucifora J,Xia YC,Reisinger F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 2014,343(6176):1221-1228.
[11] Xia YC,Stadler D,Lucifora J,et al.Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form,cccDNA,without cytolysis. Gastroenterology,2016,150(1):194-205.
[12] Xia YC,Lucifora J,Reisinger F,et al.VIROLOGY response to comment on “specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”. Science,2014,344(6189):142-144.
[13] Ramanan V,Shlomai A,Cox DBT,et al.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep-Uk,2015,5:132-136.
[14] Seeger C,Sohn JA.Complete sof CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther,2016,24(7):1258-1266.
[15] Tropberger P,Mercier A,Robinson M,et al.Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA,2015,112(42):E5715-E5724.
[16] Murphy CM,Xu YP,Li F,et al.Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep,2016,16(11):2846-2854.
[17] Streinu-Cercel A,Gane E,Cheng W,et al.A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B. J Hepatol,2017,66(1):S688-S689.
[18] Wooddell CI,Yuen MF,Chan HLY,et al.RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med,2017,9(409):182-187.
[19] Ganeea EJ. First results with RNA interference(RNAi) in chronic hepatitis B(CHB) using ARO-HBV. Hepatology,2018,68:LB-25.
[20] Fabien Zoulim JY,Vandenbossche JJ,Moscalu I,et al.Safety,pharmacokinetics and antiviral activity of a novel hepatitis B virus (HBV) capsid assembly modulator,JNJ-56136379, in patients with chronic hepatitis B (CHB). Hepatology,2018,68:47A-48A.
[21] Man-Fung Yuen KA,Gane EJ,Schwabe C,et al. Final results of a phase 1b 28-day study of ABI-H0731,a novel core inhibitor,in noncirrhotic viremic subjects with chronic hepatitis B. Hepatology,2018,68:46A-47A.
[22] Yuen MF,Kim DJ,Weilert F,et al.Nvr 3-778,a first-in-class HBVcore inhibitor,alone and in combination with peg-interferon (Pegifn),in treatment-naive Hbeag-positive patients:Early reductions in HBV DNA and HbeAg. J Hepatol,2016,64:S210-S211.
[23] Schwabe C.A phase 1 single and multiple dose-escalating study to evaluate the safety,tolerability,pharmacokinetics and effect of ARO-AAT on serum alpha-1 antitrypsin levels in normal adult volunteers. J Hepatol,2016,62:195-198.
[24] Al-Mahtab M,Bazinet M,Vaillant A.Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One,2016,11(6):e0156667.
[25] Bazinet M,Pantea V,Cebotarescu V,et al.Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF):a non-randomised,open-label,phase 2 trial. Lancet Gastroenterol Hepatol,2017,2(12):877-889.
[26] Ko C,Michler T,Protzer U.Novel viral and host targets to cure hepatitis B. Curr Opin Virol,2017,24:38-45.
[27] Xu DZ,Zhao K,Guo LM,et al.A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One,2008,3(7):e2565.
[28] Xu DZ,Wang XY,Shen XL,et al.Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients:experiences and findings. J Hepatol,2013,59(3):450-456.
[29] Wang XY,Yao X,Wan YM,et al.Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett,2013,149(1-2):88-92.
[30] Lok AS,Pan CQ,Han SHB,et al.Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol,2016,65(3):509-516.
[31] Emery JS,Feld JJ.Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Cl Ga,2017,31(3):347-355.
[32] Lobaina Y,Michel ML.Chronic hepatitis B:Immunological profile and current therapeutic vaccines in clinical trials. Vaccine,2017,35(18):2308-2314.
[33] Agarwal K,Ahn SH,Elkhashab M,et al.Safety and efficacy of vesatolimod(GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat,2018,25(11):1331-1340.
[34] Man-Fung Yuen ME,Chen CY,Chen YF,et al. Inarigivir demonstrates potent dose dependent anti-viral activity in HBV treatment-naive patients:Role of HBeAg status and baseline HBsAg in anti-viral response. Hepatology,2018,68:48A.
[35] Janssen HLA,Brunetto MR,Kim YJ,et al.Safety,efficacy and pharmacodynamics of vesatolimod(GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol,2018,68(3):431-440.
[36] Gane E,Gaggar A,Nguyen AH,et al.A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients. J Hepatol,2017,66(1):S26-S27.
[37] Mak LY,Seto WK,Fung J,et al.Novel developments of hepatitis B:treatment goals,agents and monitoring tools. Expert Rev Clin Phar,2019,12(2):109-120.

慢性乙型肝炎治愈新药研究进展

Highlights in antiviral therapy for chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	韩美玲, 陈平. 肝硬化血小板减少患者的抗病毒治疗[J]. 实用肝脏病杂志, 2019, 22(4): 466-469.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.